Technological University Dublin

ARROW@TU Dublin
Articles

School of Biological Sciences

2017

Sarcopenia: Prevalence, and Impact on Operative and Oncologic
Outcomes in the Multimodal Management of Locally Advanced
Esophageal Cancer
Jessie Elliott
Suzanne Doyle
Conor Murphy

See next page for additional authors

Follow this and additional works at: https://arrow.tudublin.ie/scschbioart
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by
the School of Biological Sciences at ARROW@TU Dublin.
It has been accepted for inclusion in Articles by an
authorized administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
Jessie Elliott, Suzanne Doyle, Conor Murphy, Sinead King, Emer Guinan, Peter Beddy, Narayanasamy Ravi,
and John Reynolds

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/318999773

Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in
the Multimodal Management of Locally Advanced Esophageal Cancer
Article in Annals of Surgery · August 2017
DOI: 10.1097/SLA.0000000000002398

CITATIONS

READS

155

406

8 authors, including:
Jessie A Elliott

Suzanne Leigh Doyle

Royal College of Surgeons in Ireland

Trinity College Dublin

119 PUBLICATIONS 830 CITATIONS

65 PUBLICATIONS 1,466 CITATIONS

SEE PROFILE

SEE PROFILE

Conor Murphy

Sinead King

St. James's Hospital

St. James's Hospital

38 PUBLICATIONS 277 CITATIONS

37 PUBLICATIONS 411 CITATIONS

SEE PROFILE

SEE PROFILE

Some of the authors of this publication are also working on these related projects:

ReStOre II- Rehabilitation Strategies Following Oesophagogastric and Hepatopancreaticobiliary Cancer View project

ReStOre Feasibility Study View project

All content following this page was uploaded by Jessie A Elliott on 30 March 2020.

The user has requested enhancement of the downloaded file.

CE: S.W.; ANNSURG-D-17-00349; Total nos of Pages: 9;

ANNSURG-D-17-00349

ESA PAPER

Sarcopenia: Prevalence, and Impact on Operative and Oncologic
Outcomes in the Multimodal Management of Locally Advanced
Esophageal Cancer
Jessie A. Elliott, MB, MRCS,  Suzanne L. Doyle, BSc, PhD,  y Conor F. Murphy, MB, BCh,  Sinead King, BSc, 
Emer M. Guinan, BSc, PhD,z Peter Beddy, MSc(RadSci), MRCPI, FRCR,§ Narayanasamy Ravi, MD, FRCS, 
and John V. Reynolds, MD, FRCS 

Objective: The aim of this article was to study the prevalence and significance of sarcopenia in the multimodal management of locally advanced
esophageal cancer (LAEC), and to assess its independent impact on operative
and oncologic outcomes.
Summary of Background Data: Sarcopenia in cancer may confer negative
outcomes, but its prevalence and impact on modern multimodal regimens for
LAEC have not been systematically studied.
Methods: Two hundred fifty-two consecutive patients were studied. Lean
body mass (LBM), skeletal muscle index (SMI), and fat mass (FM) were
determined pre-treatment, preoperatively, and 1 year postoperatively. Sarcopenia was defined by computed tomography (CT) at L3 as SMI < 52.4 cm2/m2
for males and SMI < 38.5 cm2/m2 for females. All complications were
recorded prospectively, including comprehensive complications index
(CCI), Clavien-Dindo complication (CDC), and pulmonary complications
(PPCs). Multivariable linear, logistic, and Cox regression analysis was
performed.
Results: In-hospital mortality was 1%, and CCI was 21  19. Sarcopenia
increased (P ¼ 0.02) from 16% at diagnosis to 31% post-neoadjuvant therapy,
with loss of LBM (-3.0  5.4 kg, P < 0.0001), but not FM (-0.3  2.7 kg, P ¼
0.31) during treatment. On multivariable analysis, preoperative sarcopenia
was associated with CCI (P ¼ 0.043), and CDC IIIb (P ¼ 0.003). PPCs
occurred in 36% nonsarcopenic versus 55% sarcopenic patients (P ¼ 0.01).
Sarcopenia did not impact disease-specific (P ¼ 0.14) or overall survival (P ¼
0.11) after resection. At 1 year, 35% had sarcopenia, significantly associated
with pre-treatment BMI (P ¼ 0.013) but not complications (P ¼ 0.20).
Conclusions: Sarcopenia increases through multimodal therapy, is associated
with an increased risk of major postoperative complications, and is prevalent
in survivorship. These data highlight a potentially modifiable marker of risk
that should be assessed and targeted in modern multimodal care pathways.
Keywords: body composition, body weight, CCI, chemoradiation,
chemotherapy, comprehensive complications index, computed tomography,
esophageal cancer, esophagectomy, fat mass, gastric conduit, morphometry,
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R

ecent advances in multimodal therapy, surgery, and perioperative
care have produced significant improvements in oncologic and
operative outcome for patients with esophageal cancer treated with
curative intent.1,2 Even for patients with locally advanced cancer
(LAEC), approximately half will now survive to 5 years, with the
most recent published randomized clinical trial reporting a 47% 5year survival in patients treated with multimodal therapy, and an inhospital postoperative mortality of 4%.3 This welcome progress
notwithstanding, esophageal cancer surgery is associated with significant morbidity, and with short, medium, and long-term challenges
to functional recovery and health-related quality of life (HR-QL).4 –6
In this context, the role of nutrition is paramount, with many patients
losing weight at presentation, and myriad factors, including anorexia,
early satiety, and persistent catabolism producing unintentional
weight loss and associated functional limitations in the months
following surgery or multimodal therapies.7 –10
Sarcopenia, characterized by a reduction in skeletal muscle
mass and function, is common in oncology, and is associated with
adverse outcomes for numerous cancers, including melanoma, lung,
and pancreas.11–13 The drivers of sarcopenia are multifactorial, with
physical inactivity, systemic inflammation, increased metabolic rate,
and reduced nutrient intake all contributory. These risk factors are
prevalent in esophageal cancer, and sarcopenia is reported in 26% to
75% of patients across the spectrum of disease at presentation.14– 19
Among patients with LAEC treated with curative intent, neoadjuvant
therapy may additionally reduce lean body mass (LBM); however,
whether this impacts oncologic and operative outcomes is unclear.14,16,18,20–25 Furthermore, despite the prevalence of sarcopenia
at presentation, and the weight loss trajectory observed among
disease-free patients,26 no study to date has assessed the impact of
esophageal cancer surgery on LBM and sarcopenia in survivorship.
As such, this study aimed, first, to systematically examine
changes in LBM among patients with LAEC treated with multimodal
therapy and to investigate the impact of sarcopenia on operative and
oncologic outcomes, in a high-volume European Center. Second, this
study aimed to determine the incidence of sarcopenia among diseasefree patients, and factors leading to loss of LBM in survivorship.

METHODS
Patient Selection and Study Design
The Esophageal and Gastric Centre at St. James’s Hospital,
Dublin, is a high-volume National Centre, and a detailed clinicopathologic database is prospectively maintained for all patients with
www.annalsofsurgery.com | 1
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FIGURE 1. Study design. All patients undergoing multimodal
therapy for locally advanced esophageal cancer between
January 2010 and March 2015 were considered for inclusion.
Two hundred fifty-two of 261 patients met the inclusion criteria, of whom 207 proceeded to surgical resection upon completion of neoadjuvant therapy. Of 115 patients who were
disease-free at last follow-up (median 26 months), 1-year body
composition was available for 72 patients.
esophageal cancer (Fig. 1). Records for all patients with LAEC
treated with multimodal therapy between January 2010 and March
2015 were reviewed for inclusion. Patients with a history of synchronous malignancy, eating disorder, or other illness or implant that
might alter body composition or interpretation thereof, and those
undergoing emergent surgery, salvage esophagectomy, upfront colonic, or jejunal interposition were excluded from the analysis. All
eligible patients with at least 1 preoperative computed tomography
(CT) scan capturing the level of the L3 vertebra conducted at our
Centre and available for review were included for analysis of
operative and/or oncologic outcome. To determine postoperative
changes in LBM, only disease-free patients at most recent followup, for whom both preoperative and 1-year scans were available for
analysis, were included. This study was approved by the Institutional
Review Board and registered on ClinicalTrials.gov (NCT03061370).
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During this period, patients with LAEC were treated with
neoadjuvant chemoradiation (either Cisplatin/5-Fluorouracil, 40 Gy/
15 Fr or Carboplatin/Paclitaxel, 41.4 Gy/23 Fr),27–29 or perioperative
chemotherapy (Etoposide, Cisplatin, Fluorouracil/Capecitabine).30
During neoadjuvant therapy, tailored nutritional counseling was
provided to all patients according to ESPEN best practice guidelines.31 Patients were scheduled to undergo resection approximately
6 weeks after completion of preoperative therapy, and operative
approach entailed en bloc esophagectomy with gastric conduit and
thoracic or cervical anastomosis, or extended total gastrectomy with
abdominal or thoracic Roux-en-Y reconstruction, as previously
described.1,7,32 An 8-Fr needle catheter jejunostomy was routinely
placed at surgery, with feeding commenced on the first postoperative
day and continued until at least postoperative day 21. All patients
underwent assessment at a multidisciplinary clinic at diagnosis,
before surgery, and at serial postoperative timepoints, as previously
described.10,33
Postoperative complications were coded using the ClavienDindo classification (CD) and the comprehensive complications
index (CCI).34,35 Pneumonia was defined as per CDC guidelines
and postoperative pulmonary complications (PPCs) according to
ECCG criteria.4,36 Prolonged intubation was defined as respiratory
failure of any etiology requiring reintubation or mechanical ventilation >24 hours postoperatively.

Computed Tomography Assessment of Body
Composition
Positron emission tomography with computed tomography
(PET-CT)/CT scans were routinely obtained at diagnosis, post-neoadjuvant therapy, and 1 year postoperatively using a Discovery ST
PET/CT scanner (GE Healthcare, Little Chalfont, UK) or multislice
Somatom Sensation scanner (Siemens Healthcare, Erlangen,
Germany) (Fig. 2). Images at L3 were analyzed by a single blinded
investigator (SLD) to determine the cross-sectional area (cm2) of
each tissue compartment using a Siemens Leonardo PACS Workstation (Siemens Healthcare, Erlangen, Germany), applying an automated algorithm utilizing CT Hounsfield unit thresholds of –29 to
150 for skeletal muscle and –50 to –150 for adipose tissue.37– 39
Skeletal muscle index (SMI) was derived as the ratio of lean
tissue area to height as follows:
SMI ðcm2 =m2 Þ ¼

Lean Tissue Area½L3 ðcm2 Þ
height ðm2 Þ

Sarcopenia was defined as SMI less than 52.4 cm2/m2 for men
and less than 38.5 cm2/m2 for women.37,39 LBM and fat mass (FM)

FIGURE 2. Computed tomography assessment of body composition. Abdominal computed tomography for 2 male
patients with locally advanced esophageal cancer, of body mass index 31.5 kg/m2
(A) and 32.4 kg/m2 (B). Despite similar
body mass indices, the patient in (A) has
normal lean tissue and visceral fat areas,
while the patient in (B) demonstrates
both visceral obesity and sarcopenia.
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were derived using the following formulae, which were developed
and validated against DXA as standard:37,39
LBM ðkgÞ ¼ 0:30  ½Lean Tissue Area½L3 ðcm2 Þ þ 6:06
FM ðkgÞ ¼ 0:042  ½Total Fat Area½L3 ðcm2 Þ þ 11:2
Visceral obesity was defined as visceral fat area greater than
163.8 cm2 for men and 80.1 cm2 for women.38

Sarcopenia in Esophageal Cancer

44.8% and 27.3% of patients with and without sarcopenia, respectively (OR 2.17 95% CI 1.11–4.26, P ¼ 0.01).
On multivariable analysis (Supplementary Tables 2 and 3,
http://links.lww.com/SLA/B284), preoperative sarcopenia was independently predictive of increased CCI (P ¼ 0.004), inpatient LOS
(P ¼ 0.009), major postoperative complications (IIIb, OR 5.30,
95% CI 1.94–14.45, P ¼ 0.001), PPCs (OR 2.17, 95% CI 1.12–4.23,
P ¼ 0.023), pneumonia (OR 2.33, 95% CI 1.18–4.61, P ¼ 0.015),
and prolonged intubation (OR 3.83, 95% CI 1.24–11.79, P ¼ 0.019).
Sarcopenia was not associated with in-hospital mortality (P ¼ 0.43),
which was 1.0% across the study population.

Statistical Analysis
Data were analyzed using GraphPad Prism (v.6.0) for Windows, GraphPad software (San Diego, CA) and SPSS (v.23.0)
software (SPSS, Chicago, IL). Univariable comparisons between
groups were performed using the Student t or Mann-Whitney U tests
for continuous or x2 or Fischer exact test for categorical variables.
For the multivariable analyses, all clinically relevant variables were
inputted into multivariable linear, logistic, or Cox proportional
hazards regression models using a forward stepwise selection procedure. Data are reported as mean  standard deviation unless
otherwise specified. All statistical analyses were 2-tailed with the
threshold of significance set at P < 0.05.

RESULTS
Patient Characteristics
Of 261 patients undergoing multimodal therapy during the
study period, 252 met the inclusion criteria (Fig. 1, Table 1).
Clinicopathologic characteristics of the 207 patients who proceeded
to surgical resection are detailed in Table 1. For the entire study
population, the prevalence of sarcopenia at diagnosis was 15.9%,
while 43.0% were viscerally obese, and 6.3% demonstrated both
sarcopenia and visceral obesity. Sarcopenia was significantly associated with lower body weight (P < 0.001) and BMI (P < 0.001), and
was present in 25.3% of normal weight and 10.8% of overweight
patients (Supplementary Table 1, http://links.lww.com/SLA/B284).
Sarcopenia was significantly associated with pre-treatment BMI and
SCC (P < 0.05).

Sarcopenia During Neoadjuvant Therapy
Significant LBM loss occurred during neoadjuvant therapy
(56.4  10.1 vs 53.5  9.7, -3.0  5.4 kg, P < 0.0001), with an
increase in sarcopenia from 15.9% at baseline to 30.8% preoperatively (P ¼ 0.02). No change in FM (P ¼ 0.31) was observed
following neoadjuvant therapy. LBM loss was unrelated to dysphagia
score at presentation (P ¼ 0.90), cT (P ¼ 0.27), and cN stage (P ¼
0.76). Baseline sarcopenia was not significantly associated with
disease progression (16.7 vs 7.9%, P ¼ 0.41) or impaired performance status (8.3% vs 4.7%, P ¼ 0.11); however, post-neoadjuvant
therapy, sarcopenia was associated with disease progression (19.6%
vs 4.6%, P ¼ 0.001) and performance status precluding surgery
(12.5% vs 2.1%, P ¼ 0.005).

Sarcopenia and Operative Outcome
At resection, 49 patients (25.5%) were sarcopenic, while 84
(44.0%) were viscerally obese (Table 2, Supplementary Figure 1,
http://links.lww.com/SLA/B285). Preoperative sarcopenia was associated with CCI (P ¼ 0.008), major postoperative complications
[IIIb, 24.5% vs 11.8%, odds ratio (OR) 2.41, 95% confidence
interval (95% CI) 1.05–5.48, P ¼ 0.028], and pulmonary complications (55.1% vs 35.7%, OR 2.21, 95% CI 1.15–4.28, P ¼ 0.01).
Postoperative pneumonia as per the CDC definition occurred in
ß
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Sarcopenia and Oncologic Outcome
For all patients with LAEC treated with curative intent,
sarcopenia was associated with reduced disease-specific survival
(5-year DSS, 34.2% vs 47.5%, P ¼ 0.0002), and on multivariable
analysis relative loss of LBM during treatment [hazard ratio (HR)
6.31, 95% CI 2.02–10.95] was predictive of DSS, with baseline BMI
(HR 0.92, 95% CI 0.87–0.97, P ¼ 0.002), histologic type [squamous
cell carcinoma (SCC), HR 0.29, 95% CI 0.14–0.63], cT3–4 (HR
4.78, 95% CI 1.48–15.44, P ¼ 0.009), and cNþ (HR 2.98, 95% CI
1.63–5.45) (Fig. 3).
Sarcopenia was not associated with ypT, ypN, pCR, or TRG,
but tended to be associated with reduced probability of R0 resection
(92.3 vs 81.6%, P ¼ 0.054). On multivariable analysis, independent
predictors of non-R0 resection were ypT stage (OR 5.53, 95% CI
1.98 – 15.44, P ¼ 0.001) and visceral obesity, which was protective
(OR 0.24, 95% CI 0.08–0.77, P ¼ 0.02), suggesting that the
relationship between sarcopenia and R0 resection is mediated by
reduced visceral fat planes. Despite this, sarcopenia did not significantly impact survival outcome on univariable (5-year DSS, 46.5%
vs 52.3%, P ¼ 0.14) or multivariable analysis among resected
patients (Supplementary Table 4, http://links.lww.com/SLA/B284).

Sarcopenia in Survivorship
One hundred fifteen of 207 resected patients were disease-free
after a median of 26 months of follow-up. One-year CT was available
for 72 patients (63%) (Supplementary Figure 2, http://links.
lww.com/SLA/B285). Further loss of LBM occurred during the first
postoperative year (baseline: 58.0  10.3, preoperative: 55.9  10.1,
1 year: 52.7  9.3 kg, -5.3  4.5 kg LBM, P < 0.0001), with increased prevalence of sarcopenia, from 6.9% at baseline, to 21.1%
preoperatively, and 34.7% at 1 year (P < 0.0001). Significant loss
of FM also occurred during the first postoperative year (baseline:
24.7  6.0, preoperative: 24.7  5.5, 1 year: 19.7  5.5 kg, -5.5  5.9 kg
FM, P < 0.0001).
At 1 year, sarcopenia was independently associated with lower
baseline BMI (HR 0.85, 95% CI 0.74–0.97, P ¼ 0.013) but not CCI
(P ¼ 0.20), major postoperative complication (P ¼ 0.96), anastomotic leak (P ¼ 0.15), prolonged intubation (P ¼ 0.45), operative
approach (P ¼ 0.83), histologic type (P ¼ 0.67), pT (P ¼ 0.59), or
pN stage (P ¼ 0.66), while only baseline LBM independently
predicted LBM loss (P < 0.001). Similarly, only greater baseline
FM (P ¼ 0.004) and age (P ¼ 0.02) independently predicted loss of
FM at 1 year.

DISCUSSION
This study characterized the evolution of sarcopenia through
multimodal treatment of LAEC, and in survivorship, providing novel
data suggesting that sarcopenia should be measured and recorded as a
potentially modifiable marker of risk. Sarcopenia was associated
with risk of progression during multimodal therapy, and adverse
oncologic outcomes. Moreover, muscle mass declined during
www.annalsofsurgery.com | 3
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TABLE 1. Clinicopathologic Characteristics and Preoperative Sarcopenia in Resected Population
Clinical characteristics
Age, mean (SD)
Sex, N (%)
Female
Male
Body weight, kg, mean (SD)
BMI, mean (SD)
Obesity, N (%)
Morbid obesity, N (%)
Ever smoker, N (%)
Current smoker, N (%)
Diabetes, N (%)
Cardiovascular comorbidity, N (%)
Respiratory comorbidity, N (%)
ASA grade, N (%)
Grade I
Grade II
Grade III
Neoadjuvant therapy, N (%)
Chemotherapy
Chemoradiation
Operation type, N (%)
Extended total gastrectomy
2-stage esophagectomy
3-stage esophagectomy
Transhiatal esophagectomy
Pathologic characteristics
Histologic type, N (%)
Adenocarcinoma
Squamous cell carcinoma
Clinical stage, N (%)
T1
T2
T3
T4
N0
N1
N2
N3
Pathologic stage, N (%)
T0
T1
T2
T3
T4
N0
N1
N2
N3
Tumor regression grade, N (%)
TRG 1
TRG 2
TRG 3
TRG 4
TRG 5
Not applicable
pCR, N (%)
R0 resection, N (%)
2

All patients n ¼ 207

No Sarcopenia n ¼ 143

Sarcopenia n ¼ 49

61.6 (9.3)

60.6 (8.9)

64.4 (10.1)

0.013

42
165
77.7
26.9
54
7
142
59
13
31
34

32
111
78.9
27.7
46
6
103
43
10
16
20

4
45
74.7
24.9
6
1
32
13
1
11
12

0.03

(20.3)
(79.7)
(16.0)
(4.7)
(26.5)
(3.4)
(68.6)
(28.5)
(6.3)
(15.0)
(16.4)

(22.4)
(77.6)
(15.7)
(4.5)
(32.2)
(4.2)
(72.0)
(30.0)
(7.0)
(11.2)
(14.0)

(8.2)
(91.8)
(14.7)
(4.6)
(12.2)
(2.0)
(65.3)
(26.5)
(2.0)
(22.4)
(24.5)

P

0.11
<0.001
0.008
0.68
0.37
0.72
0.30
0.059
0.12

121 (58.5)
75 (36.2)
11 (5.3)

83 (58.0)
52 (36.4)
8 (5.6)

30 (61.2)
17 (34.7)
2 (4.1)

0.88

67 (32.4)
140 (67.6)

42 (29.4)
101 (70.6)

20 (40.8)
29 (59.2)

0.14

7
26
11
5

0.89

33
114
44
16

(15.9)
(55.1)
(21.3)
(7.7)

20
82
31
10

(14.0)
(57.3)
(21.7)
(7.0)

(14.3)
(53.1)
(22.4)
(10.2)

168 (81.2)
39 (18.8)

120 (83.9)
23 (16.1)

34 (69.4)
15 (30.6)

0.037

2
28
175
2
79
99
27
2

(1.0)
(13.5)
(84.5)
(1.0)
(38.2)
(47.8)
(13.0)
(1.0)

1
22
120
0
60
64
17
2

(0.7)
(15.4)
(83.9)
(0.0)
(42.0)
(44.8)
(11.9)
(1.4)

0
5
42
2
13
26
10
0

(0.0)
(10.2)
(85.7)
(4.1)
(26.5)
(53.1)
(20.4)
(0.0)

0.08

35
28
29
105
10
113
52
24
18

(16.9)
(13.5)
(14.0)
(50.7)
(4.8)
(54.6)
(25.1)
(11.6)
(8.7)

22
20
22
72
7
82
34
16
11

(15.4)
(14.0)
(15.4)
(50.3)
(4.9)
(57.3)
(23.8)
(11.2)
(7.7)

7
6
5
28
3
23
17
3
6

(14.3)
(12.2)
(10.2)
(57.1)
(6.1)
(46.9)
(34.7)
(6.1)
(12.2)

0.75

37
43
50
49
21
7
33
186

(18.5)
(21.5)
(25.0)
(24.5)
(10.5)
(3.4)
(15.9)
(90)

24
30
40
35
11
3
22
132

(16.8)
(22.4)
(30.0)
(24.5)
(7.7)
(2.1)
(15.4)
(92.3)

7
12
7
11
9
3
6
40

(14.3)
(24.5)
(14.3)
(22.4)
(18.4)
(6.1)
(12.2)
(81.6)

0.12

2

0.13

0.25

0.82
0.054

2

Obesity, BMI >30 kg/m ; morbid obesity, BMI >40 kg/m or >35 kg/m with obesity-related comorbidity.
ASA indicates American Society for Anesthesiologists; BMI, body mass index (kg/m2); CCI, comprehensive complications index; SD, standard deviation.

neoadjuvant therapy and preoperative sarcopenia was associated
with an increased overall burden of postoperative complications, a
5-fold increased risk of major morbidity, and a 2-fold increased risk
of pulmonary complications. In disease-free survivors, the incidence
4 | www.annalsofsurgery.com

of sarcopenia continued to increase, highlighting the complexity of
unintentional weight loss in these patients.
Esophageal cancer resection is associated with significant risk
of major morbidity.5 Although a 1% in-hospital mortality reflects a
ß
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TABLE 2. Postoperative Morbidity and Preoperative Body Composition in Resected Population

Comprehensive complications index, mean (SD)
Clavien-Dindo 3b, N (%)
Clavien-Dindo grade, N (%)
No complication
Grade I
Grade II
Grade III
Grade IIIa
Grade IIIb
Grade IV
Grade IVa
Grade IVb
Grade V
Anastomotic leak, N (%)
Postoperative pulmonary complications, N (%)
Pneumonia, N (%)
Prolonged intubation, N (%)
Atrial fibrillation, N (%)
Major cardiac morbidity, N (%)
In-hospital mortality, N (%)

All patients
n ¼ 207

No Visceral
Obesity n ¼ 107

Visceral
Obesity n ¼ 84

P

No Sarcopenia
n ¼ 143

Sarcopenia
n ¼ 49

P

20.6 (18.7)
30 (14.5)

20.1 (20.5)
16 (15.0)

21.4 (17.2)
12 (14.3)

0.64
0.90

18.6 (18.2)
17 (11.8)

26.6 (20.8)
12 (24.5)

0.008
0.028

57 (27.5)
26 (12.6)
69 (33.3)

30 (28.0)
20 (18.7)
25 (23.4)

23 (27.4)
5 (6.0)
34 (40.5)

44 (30.8)
20 (14.0)
45 (31.5)

10 (20.4)
5 (10.2)
15 (30.6)

25 (12.1)
6 (2.9)

16 (14.9)
4 (3.7)

9 (10.7)
1 (1.2)

17 (11.8)
1 (0.7)

7 (14.3)
4 (8.2)

11
11
2
10
84
66
22
41
4
2

5
5
2
3
40
29
12
14
2
2

(5.3)
(5.3)
(1.0)
(4.8)
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Sarcopenia and visceral obesity defined by preoperative computed tomography.
SD indicates standard deviation.
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FIGURE 3. Sarcopenia at presentation and disease-specific survival, Among all patients treated with neoadjuvant therapy, baseline
sarcopenia was associated with reduced disease-specific survival (P ¼ 0.0009, left); however, sarcopenia did not impact survival
outcome among those who proceeded to planned surgical resection following completion of neoadjuvant treatment (P ¼ 0.14,
right). Log-rank test.
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high-volume experience, consistent with others,40 pulmonary morbidity when accurately and prospectively documented remains high.
Using the CDC clinical definition of pneumonia, with radiologic,
laboratory, and clinical features as criteria, irrespective of sputum or
blood culture,36 the overall incidence is high at 32%, but significantly
more prevalent among patients with preoperative sarcopenia, at 45%
compared with 27%. This is consistent with Japanese series: Nishigori et al14 reported an approximate 3-fold increase in PPCs among
patients with sarcopenia, and Ida et al15 reported a 5-fold increased
risk of PPCs with lower LBM. These series were exclusively SCC,
with mean BMIs of 21 and 22 kg/m2 and preoperative sarcopenia
rates of 75% and 44%, respectively, compared with 27 kg/m2 and
31% herein. Conversely, in a study of 120 patients treated with
neoadjuvant CROSS, 45% with baseline sarcopenia, Grotenhuis
et al16 identified no significant impact of sarcopenia at presentation
on operative outcome, although analysis of only the pre-chemoradiation CT may have meant that LBM measures did not reflect
muscle mass at operation, something acknowledged by the authors as
a limitaton. In the present study, sarcopenia was not associated with
anastomotic complications or atrial fibrillation, the latter more
common among patients with visceral obesity. Notably, sarcopenia
was associated with increased operative morbidity independent of
body weight or BMI, something not previously reported.
The mechanism linking reduced muscle mass to postoperative
respiratory morbidity is unclear. Sarcopenia reduces maximum
inspiratory pressure, forced expiratory volume 1 second, and forced
vital capacity in older adults, theoretically increasing risk of mucus
plugging and atelectasis.23,41,42 Sarcopenia is also associated with
increased insulin resistance and higher circulating levels of proinflammatory cytokines, possibly contributing to risk of postoperative
acute lung injury,14 while globally impaired muscle function may
additionally impact oropharyngeal motility, resulting in impaired
swallow function and increased aspiration risk.43,44 Prehabilitation
programs in esophageal cancer targeting inspiratory muscle training,
aiming to achieve a reduction in PPCs, hence have considerable
theoretical rationale.45
Neoadjuvant therapy in esophageal cancer is generally associated with clinical improvement in dysphagia, yet paradoxically the
incidence of sarcopenia significantly increased, from 16% to 31%,
with mean loss of 3 kg LBM. Awad et al,18 in 47 patients undergoing
preoperative chemotherapy for esophageal and gastric cancers,
demonstrated an LBM loss of 2.9  4.7 kg, and Yip et al25 reported
an increase in sarcopenia from 26% to 43% following chemotherapy
in LAEC. Although the physiologic drivers of this significant decline
in muscle mass are unclear, the relative preservation of FM suggests a
direct effect with respect to skeletal muscle. In this regard, cytotoxic
agents may impair myocellular proliferation and protein synthesis by
disrupting the mammalian target of rapamycin (mTOR) kinase
signaling pathway,46 while cisplatin also promotes muscle wasting
through a number of mechanisms including impaired Akt phosphorylation, leading to sustained activation of the degradative proteasome
and autophagy systems, and altered NF-kB signaling.47,48 Sarcopenia was associated with worsened performance status and disease
progression, precluding surgical resection. Whether this reflects
reduced volume of effective distribution of chemotherapy, enabling
increased toxicity, is unclear, but is an important question for further
study, particularly in the context of recent data demonstrating an
almost 3-fold increased rate of dose-limiting chemotoxicity with
sarcopenia in esophageal cancer.18,20,24 The complex interplay between baseline sarcopenia and oncologic outcome is highlighted by
reduced DSS with sarcopenia among all LAEC patients, but not
among those proceeding to surgery post-neoadjuvant therapy. Future
studies assessing the role of LBM-based dosing, versus conventional
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BSA-based calculations, are consequently of great interest in this
context (eg, NCT01624051).
With improved oncologic outcomes, and low operative mortality, there is currently a major focus on survivorship and quality of
life.6–10 Weight loss is a significant issue, and seminal papers from
Sweden highlighted that over two-thirds of patients experience
>10% body weight at 6 months, while one-third of patients lose
15% body weight at 5-year follow-up.26,49 Although clearly linked
to sarcopenia, no previous study has described the underlying
changes in body composition in survivorship. In the current study,
continued loss of muscle mass was observed, with a 5-fold increase
compared with initial presentation, while in a cohort of 50 patients
who had surgery only (data not shown), the prevalence of sarcopenia
at 1 year was 37.5%, hence ongoing muscle loss appears independent
of neoadjuvant therapy. Although loss of LBM may reduce strength
and mobility, corroborating measures of functional performance
were not conducted, which we acknowledge as a limitation.43 In
the context of a survivorship program recently established at this
Center, a feasibility project demonstrated that a 12-week multimodal
rehabilitation program, including supervised exercise, dietetic
counseling, and multidisciplinary education, was associated with
increased indices of physical function and HR-QL, and reduced
circulating inflammatory markers among disease-free patients postesophagectomy;50 an RCT examining this approach is ongoing.
In conclusion, sarcopenia, very simply diagnosed by routine
staging CT, is common in LAEC, increased by neoadjuvant therapy,
and independently associated with postoperative morbidity. Sarcopenia is prevalent in survivorship. Measures of muscle mass and
function, and targeted approaches through multimodal protocols
and in survivorship, have appeal in the evolving goals to optimize
a complex attritional cancer treatment protocol and improve
survivorship.
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DISCUSSANTS
Bruno Walther (Lund, Sweden):
Thank you for the opportunity to discuss this interesting paper.
It is well known that esophageal cancer patients lose weight, but
sarcopenia is previously not described in detail from diagnosis to
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1 year after oncological and surgical therapy. I have the following
questions and remarks: First, please rank the importance of the
different factors inducing sarcopenia in the resected patients? Second, in your study, 16% of the patients had sarcopenia at study start
and 35% after 1 year. We have found that there is a strong correlation
between anastomotic diameter and gain in weight. No matter how
you define it, was sarcopenia more common in patients with strictures? In our study comparing neck and chest anastomoses after
esophagectomy in radio-chemonaive patients (Ann Surg 2003; 238:
803–812), the weight loss leveled away after 3 months and the
patients start to gain weight.
Third, enteral nutrition enriched with eicosapentaenoic acid
(EPA) preserves lean body mass (LBM) following esophageal cancer
surgery, as your group wrote in Annals of Surgery (Ann Surg 2009;
249: 355–363). In the present study, there is a loss of LBM during the
first postoperative year. Please clarify the difference between the
studies. Do you still use EPA in the nutritional support?
Fourth, do you use full stomach as a substitute, proposed by
Collard and others, or do you modify the stomach to a gastric tube
used for morbid obesity? This is because the weight reduction and
sarcopenia seen in your surgical patients might to some extent be
explained by the way the stomach is modified to substitute the
resected esophagus. Finally, congratulations to an important study
and an excellent presentation.

Response from Jessie A. Elliott (Dublin, Ireland):
Thank you, Professor Walther for your comments and your
questions, which I will address in sequence. First, in terms of
sarcopenia before resection, we found that sarcopenia was associated
with older age, male sex, lower body mass index, and LBM at
diagnosis, SCC, and tended to be associated with a cardiovascular
comorbidity. We did also identify a significant association between
sarcopenia and clinically node-positive disease at the preoperative
time point. And, then looking forward into survivorship in the
resected population, among disease-free patients at 1 year postoperatively, the only independent factor tested that predicted sarcopenia
in that cohort was baseline LBM. Interestingly, even though we
assessed factors such as length of stay, critical care length of stay, and
perioperative complications in a multivariate model, none of these
predicted long-term change in LBM in these patients. For this reason,
we are suggesting that not only other mechanisms, for example, as
you mentioned anastomotic stricture, but also changes in appetite,
gut hormones, and gut function might underline the long-term
changes in body composition observed in this cohort. I think this
is something that requires further study.
The second question you had was about the prevalence of
anastomotic stricture in the sarcopenic patients at follow-up. We did
not identify any statistically significant difference in the prevalence
of strictures between sarcopenic and nonsarcopenic patients. However, this needs to be examined in a dedicated study to determine the
role of anastomotic strictures in the postoperative loss of LBM
after esophagectomy.
Third, you asked us about whether we were still using EPAsupplemented feeds in our patient cohort. The answer is no, and the
rationale for this has been discussed earlier this morning. A proportion of the patients in the study may have received EPA-supplemented feed, but given our recent data, this should not have impacted
their LBM at the time of surgery, or postoperatively.
The final question was in relation to the gastric conduit that we
use. So, this is a 5 cm greater curvature gastric conduit, which has
been described in detail in a number of our studies (World J Surg
2017; 41:487–497 and Ann Surg 2017; 266:82–90). It is certainly
possible that this reconstruction may be contributing to a bariatriclike mechanism in our patient cohort. The other possible operative
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factor that may contribute to a bariatric-like mechanism is pyloric
management. In our center, pyloroplasty is performed as routine. We
have shown that these patients demonstrate a greatly exaggerated
postprandial satiety gut hormone response, which may be related to
rapid gastric conduit emptying. However, no study so far has looked
at the differences in gut hormone physiology and appetite among
patients with gastric conduit versus whole stomach reconstruction,
and I think that is something that could be very interesting to assess in
the future.

P. Ronan O’Connell (Dublin, Ireland):
Thank you chairman. Jessie, congratulations on a wonderful
presentation. I have 3 quick questions: First, was there a difference in
the complication rates between those who were sarcopenic ab initio
and those who developed sarcopenia as a result of chemoradiotherapy? Second, did the sarcopenia progress in those who were sarcopenic ab initio and if so did they have a worse outcome? This
leads me to the last point, if you identify somebody with sarcopenia
pre-chemoradiotherapy is that a diagnosis that would make you
think that the patient should go directly to surgery and not have
chemoradiotherapy?

Response from Jessie A. Elliott (Dublin, Ireland):
Thank you, Professor O’Connell for these interesting questions. We did look at the role of baseline sarcopenia for predicting
postoperative complications. Baseline sarcopenia tended to be associated with increased postoperative complications (P ¼ 0.095), and
was associated with an increased risk of pulmonary complications
(P ¼ 0.02). However, preoperative sarcopenia measures were more
accurate than baseline measures for prediction of postoperative
outcomes.
We also looked at patients who were sarcopenic at presentation versus patients who became sarcopenic during neoadjuvant
therapy. We did not see any difference in the overall burden of
complications experienced by incident sarcopenic patients versus
baseline sarcopenic patients. Patients who were sarcopenic at baseline continued to lose LBM (1.1  1.4 kg), but this was less
pronounced compared with nonsarcopenic patients (5.7  0.8 kg,
P ¼ 0.02), and the overall burden of complications was similar
among all patients with sarcopenia (whether progressive or stable
during neoadjuvant therapy, P ¼ 0.80).
The third question was should sarcopenic patients be considered for surgery upfront? I think the answer to that is no – We know
that these patients have a much better oncologic outcome after
neoadjuvant therapy. The way I see it, we have this great therapeutic
window to intervene among patients undergoing neoadjuvant therapy, to try and improve their performance status and achieve a better
postoperative outcome. Therefore, I think the main message arising
from these data is that there is a potential opportunity to improve
outcomes through preoperative prehabilitation in this cohort, and the
efficacy of such an approach requires further assessment.

Christophe Mariette (Lille, France):
Thanks a lot Jessie, definitely a very nice presentation, so
congratulations. I have 2 short questions based on the methodology.
My first question is regarding the multivariable model. Do you think
it is useful to put so many variables in the model that may have some
interactions altogether? My recommendation would have been to put
in the multivariable model (i) clinically relevant variables (and not all
the statistically significant in univariable analysis), and (ii) the
variables without strong known interactions.
The second question is why were the reoperations excluded
from the analysis? It could have been a good marker of the negative
impact of sarcopenia on outcomes.
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In addition, I just want to highlight that in general in medicine,
statistically significant does not always mean clinically relevant.

Response from Jessie A. Elliott (Dublin, Ireland):
Thank you, Professor Mariette for your questions and comments. In terms of the multivariable models, we endeavor to avoid
issues with collinearity. There are a couple of important things to note
about the multivariable models we used. First, for this study, our
models used a forward stepwise selection procedure, so that means
that the model selects the first variable based on the variable with the
strongest univariable correlation to the outcome, thereafter further
variables are inputted into the model based on the residual variability
in the outcome. So, the number of variables first presented to the
model is less problematic, because only the variables that are
significant on univariable analysis are actually inputted into the
model in a stepwise approach. Rules of thumb regarding sample
size and covariate count in regression oversimplify the issue considerably. In fact, the sample size required in terms of number of
covariates depends on the expected effect size, the required power,
and the output of interest.
Second, the aim of our multivariable analysis was to probe for
variables that were most strongly predictive of operative outcome,
rather than choosing known factors and feeding them into the model.
We were interested in identifying which factors most strongly
impacted outcome in our cohort, rather than controlling for certain
factors and looking at the impact of another. So, it is a different
analytical approach.
With respect to reoperation, we did include patients with
Clavien-Dindo grade IIIb. So, patients who returned to theater for
a complication were included. We did not include salvage esophagectomy because we felt that this cohort was likely at a great risk of
baseline sarcopenia and they are likely at an increased risk of
complications – We felt that it would increase the heterogenity of
the cohort and dilute the message. Our numbers for salvage would
also be quite small, so we would not have the power to analyze them
separately from our main study population.

Richard van Hillegersberg (Utrecht, The
Netherlands):
Thank you very much for a well-conducted important study on
this topic. I have a question about the neoadjuvant chemoradiotherapy or chemotherapy. Do you have an explanation why these patients
deteriorate under this neoadjuvant treatment? In our experience
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during the neoadjuvant chemoradiotherapy, a lot of patients who
respond well get into an anabolic state because they are allowed to eat
again or have nutritional support. Furthermore, did you look into the
toxicity profiles of chemotherapy versus chemoradiotherapy and did
you look into the group that responded well to the neoadjuvant
treatment?

Response from Jessie A. Elliott (Dublin, Ireland):
Thank you for these questions. What is very interesting, I
think, about the changes in body composition during neoadjuvant
therapy is that it was a very specific loss of LBM that occurred and
actually the fat mass was completely stable, which would sort of
imply that this is some kind of specific myotoxic effect. In that
regard, it is known that a number of the chemotherapeutic agents
used in esophageal cancer can have a direct effect on muscle
proliferation and myocyte protein synthesis, through various pathways including mTor and NFKB signaling. It is possible that there is
a direct myotoxic effect of the chemotherapeutic agents.
In that regard, interestingly in other malignancies, some
groups are now looking at the use of LBM-based calculations for
chemotherapy dosing, rather than basing it on body surface area,
which is the current standard. It may be that patients who are
sarcopenic will accumulate a higher dose of these hydrophilic drugs
in their muscle and therefore be at an increased risk of chemotherapy
toxicity. The toxicity profiles were not specifically captured in this
particular study. It is certainly something that could be studied
further. There are 2 previous studies (Eur J Surg Oncol 2015;
41:333–338 and Clin Nutr 2016; 35:724–730), one from Sweden
and one from the UK looking at the role of sarcopenia in terms of risk
from chemotherapy toxicity in the neoadjuvant context in esophageal
and gastric cancer, and both showed that patients with sarcopenia at
baseline are at an increased risk of toxicity. Certainly, it is something
that warrants more study going forward.
On multivariable analysis, we did not find any difference
between chemotherapy and chemoradiation in terms of risk of
sarcopenia either in the population overall, or in adenocarcinoma
patients alone. It is certainly something that could be looked at in the
ongoing trials.
In terms of sarcopenia in responders versus nonresponders,
there was no difference in prevalence of preoperative sarcopenia
according to the presence of pCR among all patients (21% vs 26%, P
¼ 0.82), and pCR was not independently predictive of preoperative
sarcopenia on multivariable analysis.
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